Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk | Zendy

Zoe Moodie | Zendy; One Dintwe | Zendy; Sheetal Sawant | Zendy; Doug Grove | Zendy; Yunda Huang | Zendy; Holly Janes | Zendy; Jack Heptinstall | Zendy; Faatima Laher Omar | Zendy; Kristen W. Cohen | Zendy; Stephen C. De Rosa | Zendy; Lu Zhang | Zendy; Nicole L. Yates | Zendy; Marcella SarzottiKelsoe | Zendy; Kelly E. Seaton | Zendy; Fatima Laher | Zendy; LindaGail Bekker | Zendy; Mookho Malahleha | Zendy; Craig Innes | Zendy; Sheetal Kassim | Zendy; Nivashnee Naicker | Zendy; Vaneshree Govender | Zendy; Modulakgotla Sebe | Zendy; Nishanta Singh | Zendy; Philip Kotze | Zendy; Erica Lazarus | Zendy; Maphoshane Nchabeleng | Zendy; Amy Ward | Zendy; William Brumskine | Zendy; Thozama Dubula | Zendy; April Randhawa | Zendy; Nicole Grunenberg | Zendy; John Hural | Zendy; Jia Jin Kee | Zendy; David Benkeser | Zendy; Yutong Jin | Zendy; Lindsay N. Carpp | Zendy; Mary Allen | Zendy; Patricia D’Souza | Zendy; James Tartaglia | Zendy; Carlos A. DiazGranados | Zendy; Marguerite Koutsoukos | Zendy; Peter B. Gilbert | Zendy; James G. Kublin | Zendy; Lawrence Corey | Zendy; Erica AndersenNissen | Zendy; Glenda Gray | Zendy; Georgia D. Tomaras | Zendy; M. Juliana McElrath | Zendy

Open Access

Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

Author(s) -

Zoe Moodie,

One Dintwe,

Sheetal Sawant,

Doug Grove,

Yunda Huang,

Holly Janes,

Jack Heptinstall,

Faatima Laher Omar,

Kristen W. Cohen,

Stephen C. De Rosa,

Lu Zhang,

Nicole L. Yates,

Marcella SarzottiKelsoe,

Kelly E. Seaton,

Fatima Laher,

LindaGail Bekker,

Mookho Malahleha,

Craig Innes,

Sheetal Kassim,

Nivashnee Naicker,

Vaneshree Govender,

Modulakgotla Sebe,

Nishanta Singh,

Philip Kotze,

Erica Lazarus,

Maphoshane Nchabeleng,

Amy Ward,

William Brumskine,

Thozama Dubula,

April Randhawa,

Nicole Grunenberg,

John Hural,

Jia Jin Kee,

David Benkeser,

Yutong Jin,

Lindsay N. Carpp,

Mary Allen,

Patricia D’Souza,

James Tartaglia,

Carlos A. DiazGranados,

Marguerite Koutsoukos,

Peter B. Gilbert,

James G. Kublin,

Lawrence Corey,

Erica AndersenNissen,

Glenda Gray,

Georgia D. Tomaras,

M. Juliana McElrath

Publication year - 2022

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiac260

Subject(s) - hiv vaccine , immunology , immunogenicity , vaccine trial , medicine , hazard ratio , antibody , vaccine efficacy , proportional hazards model , virology , confidence interval

The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk in RV144 were measured in HVTN 702 and evaluated as correlates of HIV-1 acquisition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research